



CONTACTS & KEY INFORMATION

Headquarters:

Bone Solutions Inc.
10,000 No. Central Expwy, Ste 900
Dallas, TX 75231
Ph: 214 234 0661 Fx: 800 417 8196

Capital Status:

BSI is privately held, with management having controlling ownership. All funding to date has been through Angel and Management Team investors.

Website:

www.bonesolutionsinc.com

Sector:

Medical Device: Orthopedics, Orthopedic Biologics

Investor Contact:

Tony Copp, EVP/COO
Bone Solutions Inc.
Ph: 214 762 8066 214 738 7973

Media Contact:

Ronald C. Trahan, President
Ronald Trahan Associates Inc.
508 359 4005, x108

MANAGEMENT TEAM

Thomas J. Lally

Founder and President

Tony Copp, Ph.D. (Economics)

Chief Operating Officer

James McNamara

Treasurer and Director

Drew Diaz, Phil Holcombe and W. B. Hampton

Directors

Stephen A. Schendel, M.D., D.D.S.

Chief Medical Officer

SCIENTIFIC ADVISORY BOARD

Alicia L. Bertone, Ph.D. (Chair)

Ohio State University

Edward Mills, D.D.S.

Center for Restorative Dentistry

James Montgomery, M.D.

Orthopedic Specialists of Dallas

Michael A. Pikos, M.D., D.D.S.

MAP Implant Institute

John Russo, M.D., D.D.S.

International Congress of Oral Implantologists

Stephen A. Schendel, M.D., D.D.S.

Stanford University Medical Center

Tarek O. Souryal, M.D.

Sports Medicine Clinic of Dallas

Richard Steadman, M.D.

Steadman-Hawkins Clinic

Thomas G. Wilson, Jr., D.D.S.

U. of Texas Dental School; Baylor College of Dentistry

Nancy Lynch, M.D.

Principal, Scale Venture Partners

HIGHLIGHTS...

► **BSI is establishing its novel *magnesium* oriented platform** as a major new technology for the orthopedics industry, providing a solution for orthopedic surgeons for both human and veterinary uses with a *magnesium*-based compound—available for the first time in orthopedic medical history. None of the leading *calcium*-based filler products in bone repair or replacement has significant binding qualities nor are they resorbable. The first *magnesium*-based application is *OsteoCrete*[™] for human applications, and is expected to fill a current void in medical procedures by improving upon existing filler/cement devices with its bioabsorbable qualities to more effectively repair, at lower cost, many non-load bearing injuries. *OsteoCrete* is cleared by the FDA in a 510 (k) clearance as a bone void filler for long-bone and pelvis applications; BSI intends to submit future 510(k) applications seeking approval to market variations of its initial product as an anchor, bone cement, and filler for maxillofacial/cranial applications and non-load-bearing spine.

► **Orthopedic surgeries have a wide range of failure rates** due to the technical limitations of bone fillers, cements, anchors and metal-fixation devices used in these surgeries. (For example, 'Rotator Cuff' surgeries alone are only 50 percent successful.) Most products today are *calcium phosphate*-based, which does not have any powerful binding qualities. Many orthopedic surgeons do not even bother using today's fillers and cements, knowing their deficiencies—and in some cases have used and then discontinued the use of certain cements and fillers. Indeed, the industry spends millions of dollars annually on new R&D in an attempt to invent better *calcium*-based products, or better-reinforcing metallic devices such as nails, pins, plates, and screws—some of which are not bioabsorbable—to compensate for the significant limitations of today's *calcium*-based fillers and cements.

► **BSI seeks to position its technology platform** for new approaches to orthopedic surgery repair. BSI already has been issued the seminal patent as an adhesive from the USPTO, has filed for four additional patents, and has received FDA 510(k) clearance for its first device, *OsteoCrete*[™]—as a bone void filler for long-bone and pelvis applications; and thereafter, in subsequent FDA filings, as a cement, bone anchor, bone void filler for cranial and separately for maxillofacial applications, and for non-load-bearing spine. BSI is commencing sales efforts in human markets. BSI controls all global market applications for any human and nonhuman use of its technologies. BSI is in discussions with companies that constitute more than 90 percent of the orthopedic industry worldwide to explore the opportunity for strategic alliances.

► **Rigorous testing of BSI's first FDA-cleared product, *OsteoCrete*[™], was performed at The Ohio State University** by Dr. Alicia Bertone, Professor and Trueman Family Endowed Chair, Comparative Orthopedic Research Laboratories; and by Dr. Scott Rodeo, Hospital for Special Surgery, NYC; and by NAMS, Toledo, Ohio; and Geneva Laboratories, Elkhorn, Wyo. The results of several of Dr. Bertone's and Dr. Rodeo's studies have been presented at the Orthopedics Research Society/AAOS Annual Scientific Meetings; and Dr. Schendel and Dr. Rodeo have also published their *OsteoCrete*[™] studies. BSI believes that *OsteoCrete* will be seen as a novel new solution for bone and ligament surgical operations for both human and animal applications worldwide.